openPR Logo
Press release

Prostate Cancer Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight

04-22-2025 01:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Prostate Cancer Clinical Trials

Prostate Cancer Clinical Trials

Prostate cancer companies are Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen, more
(Albany, USA) DelveInsight's 'Prostate Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline prostate cancer in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.

As per DelveInsight's assessment, globally, Prostate Cancer pipeline constitutes 150+ key companies continuously working towards developing 160+ Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Request a sample and discover the recent advances in prostate cancer drugs @ Prostate Cancer Pipeline Report [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Takeaways from the Prostate Cancer Pipeline Report

* DelveInsight's prostate cancer pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline prostate cancer drugs.
* Key prostate cancer companies such as Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others are evaluating new prostate cancer drugs to improve the treatment landscape.
* Promising pipeline prostate cancer such as 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others are under different phases of prostate cancer clinical trials.
* In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
* In August 2024, Nuvation Bio announced that the US Food and Drug Administration cleared its investigational new drug application to evaluate NUV-1511, the first clinical candidate from the company's novel drug-drug conjugate (DDC) platform.
* In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
* In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
* In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer ("CRPC") who have progressed on or after standard systemic regimens.
* In May 2024, Fusion Pharmaceuticals began the Phase II AlphaBreak trial of FPI-2265 in mCRPC patients.
* In February 2024, Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre. The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture, and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers. In addition, Fusion and the Licensors have signed an agreement to settle the parties' dispute related to an inter partes review of a U.S. patent owned by the Licensors which was instituted in August 2023 by the United States Patent and Trademark Board.
* In February 2024, BioXcel Therapeutics, Inc. announced that the FDA granted Fast Track designation for BXCL701 with a CPI to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy. This designation allows for expedited development and review by the FDA.

Find out more about prostate cancer drugs @ Prostate Cancer Pipeline Analysis [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Prostate Cancer Overview

Prostate Cancer is one of the most common types of cancer affecting men, especially those over the age of 50. Prostate Cancer begins in the prostate gland, a small walnut-shaped gland that produces seminal fluid. Prostate Cancer often develops slowly and may not cause noticeable symptoms in its early stages. However, advanced Prostate Cancer can lead to difficulties in urination, blood in urine and pelvic discomfort.

Prostate Cancer diagnosis typically involves prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), imaging studies, and biopsies to confirm the presence and stage of the disease. Prostate Cancer risk factors include age, family history, race, and lifestyle choices.

Prostate Cancer treatment options vary depending on the stage and aggressiveness of the disease and may include active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, and immunotherapy. Prostate Cancer patients are also increasingly benefiting from precision medicine and targeted therapies designed to minimize side effects and improve outcomes.

Prostate Cancer awareness and early detection through regular screening play a critical role in improving survival rates. Ongoing research in Prostate Cancer continues to explore advanced diagnostic tools and more effective treatment approaches to enhance patient care.

Currently approved drugs for metastatic prostate cancer include XTANDI by Astellas/Pfizer and ZYTIGA by Janssen, both available for over a decade. Despite the introduction of ZYTIGA generics in the US in 2019 and in the EU since late 2022, causing a significant revenue drop, particularly in the US, ZYTIGA is still being actively studied in combination with emerging therapies, boosting its use with the compound abiraterone acetate.

In 2019, Janssen expanded its portfolio with ERLEADA for mHSPC, following its 2018 approval for nmCRPC. Bayer's NUBEQA has also rapidly gained momentum, becoming a key competitor. PARP inhibitors have been making strides for patients with HRR gene mutations (BRCA1/2). AstraZeneca's LYNPARZA was introduced for first-line prostate cancer treatment, while Pharma& Schweiz's RUBRACA became available for 3L mCRPC patients in 2020. Additionally, in 2023, Pfizer's TALZENNA, Janssen's AKEEGA, and AstraZeneca/Merck's LYNPARZA were approved for first-line use. Myovant Sciences' ORGOVYX and Sanofi's JEVTANA have also been approved in the US for treating mCRPC.

In 2022, Novartis' radioligand therapy, PLUVICTO, was approved for mCRPC treatment, resulting in higher-than-expected revenue in the third-line mCRPC segment. Novartis now plans to expand its presence into earlier-line mCRPC by 2024 and mHSPC by 2025 within the US market.

For further information on the prostate cancer pipeline therapeutics, reach out @ Prostate Cancer Therapeutics Market [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

A snapshot of the Pipeline Prostate Cancer Drugs mentioned in the report:

* 177Lu-PSMA-I&T: Curium
* Opevesostat (MK-5684; ODM-208): Merck/ Orion
* Mevrometostat (PF-06821497): Pfizer
* TRUQAP (capivasertib, AZD5363): AstraZeneca
* 177Lu-PNT2002: Lantheus
* 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
* TAVT-45 (abiraterone acetate): Tavanta Therapeutics
* Saruparib (AZD5305): AstraZeneca
* CAN-2409 (aglatimagene besadenovec): Candel Therapeutics
* Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Learn more about the emerging prostate cancer therapies @ Prostate Cancer Clinical Trials and FDA Approvals [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Prostate Cancer Therapeutics Assessment

The prostate cancer pipeline report proffers an integral view of the emerging prostate cancer segmented by stage, product type, molecule type, route of administration, and mechanism of action.

Scope of the Prostate Cancer Pipeline Report

* Coverage: Global
* Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
* Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
* Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
* Therapeutics Assessment By Mechanism of Action: PSMA inhibitors (Prostate-specific Membrane Antigen Inhibitors), CYP11A1 inhibitor, EZH2 inhibitor, Proto-oncogene protein c-akt inhibitor, PSMA-targeted therapy, Ionising radiation emitter, Steroidal inhibitor of CYP17A1, Poly(ADP-ribose) polymerase-1 inhibitor, Thymidine kinase expression stimulants, Poly(ADP-ribose) polymerase 2 inhibitors
* Key Prostate Cancer Companies: Merck & Co., Inc. (NYSE: MRK), Telix Pharmaceuticals Limited (ASX: TLX), Exelixis, Inc. (NASDAQ: EXEL), AstraZeneca PLC (NASDAQ: AZN), AB Science S.A. (EPA: AB), Lantheus Holdings, Inc. (NASDAQ: LNTH), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), MacroGenics, Inc. (NASDAQ: MGNX), Xencor, Inc. (NASDAQ: XNCR), Merus N.V. (NASDAQ: MRUS), Arvinas, Inc. (NASDAQ: ARVN), Candel Therapeutics, Inc. (NASDAQ: CADL), Ipsen S.A. (EPA: IPN), LAVA Therapeutics N.V. (NASDAQ: LVTX), ESSA Pharma Inc. (NASDAQ: EPIX), Poseida Therapeutics, Inc. (NASDAQ: PSTX), Janux Therapeutics, Inc. (NASDAQ: JANX), AbbVie Inc. (NYSE: ABBV), Sorrento Therapeutics, Inc. (OTC: SRNEQ), Avacta Group plc (LSE: AVCT), BeiGene, Ltd. (NASDAQ: BGNE), Duality Biologics (HKEX: 6988), Curium, Modra Pharmaceuticals, Syntrix Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Blue Earth Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, SL VAXiGEN, Nammi Therapeutics, and 858 Therapeutics, and others
* Key Prostate Cancer Pipeline Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others

Dive deep into rich insights for new prostate cancer treatments, visit @ Prostate Cancer Drugs and Therapies [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Prostate Cancer Pipeline Report Introduction

2. Prostate Cancer Pipeline Report Executive Summary

3. Prostate Cancer Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Prostate Cancer Clinical Trial Therapeutics

6. Prostate Cancer Pipeline: Late-Stage Products (Pre-registration)

7. Prostate Cancer Pipeline: Late-Stage Products (Phase III)

8. Prostate Cancer Pipeline: Mid-Stage Products (Phase II)

9. Prostate Cancer Pipeline: Early-Stage Products (Phase I)

10. Prostate Cancer Pipeline Therapeutics Assessment

11. Inactive Products in the Prostate Cancer Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Companies

14. Key Products in the Prostate Cancer Pipeline

15. Unmet Needs

16. Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prostate-cancer-clinical-trials-analysis-2025-ema-pdma-fda-approvals-clinical-trials-therapies-medication-nda-approval-ind-mechanism-of-action-route-of-administration-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Prostate Cancer Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight here

News-ID: 3981411 • Views:

More Releases from ABNewswire

Affordable MLB Postseason Tickets Online: Use Promo Code CITY10 at CapitalCityTickets.com
Affordable MLB Postseason Tickets Online: Use Promo Code CITY10 at CapitalCityTi …
Get your MLB postseason tickets online at CapitalCityTickets.com and enjoy affordable pricing! Use promo code CITY10 at checkout to save on every game. From wild-card matchups to the World Series, fans can secure the best seats at stadiums nationwide. Don't miss the excitement of playoff baseball - buy your tickets today and cheer on your favorite team without overspending. The 2025 MLB postseason is here, and the excitement is electric! Whether
Secure Nets Barclays Center Tickets Fast: Save with CITY10 at CapitalCityTickets.com
Secure Nets Barclays Center Tickets Fast: Save with CITY10 at CapitalCityTickets …
Score your Brooklyn Nets tickets at Barclays Center quickly and easily with CapitalCityTickets.com! Fans can save instantly using promo code CITY10. Whether you want courtside action or upper-level seats, get the best deals for every home game. Don't miss live NBA action featuring Kevin Durant, Kyrie Irving, and the Nets - buy your tickets online today for the 2025-26 season. Ready to catch the Brooklyn Nets in action at the iconic
Best Boston Celtics Home Game Tickets: Save Big at CapitalCityTickets.com with Promo Code CITY10
Best Boston Celtics Home Game Tickets: Save Big at CapitalCityTickets.com with P …
Score the best deals on Boston Celtics home game tickets at TD Garden with CapitalCityTickets.com! Whether you're sitting courtside or in the balcony, fans can save big by using promo code CITY10 at checkout. Don't miss a chance to watch Jayson Tatum, Jaylen Brown, and the Celtics dominate on their home court. Buy your tickets online today and enjoy unbeatable prices for every matchup in the 2025-26 NBA season. Are you
"Faces of Psychosis" Redefines Art and Memoir with Unflinching Vision
Image: https://www.abnewswire.com/upload/2025/09/0dee09b98e12efa62723aec52dbb43c5.jpg Shoreline, WA - Jairus Beane's Faces of Psychosis has ignited critical acclaim as a genre-defying masterpiece that fuses memoir, avant-garde photography, and mental health advocacy. Released today, the groundbreaking work, featuring 92 unaltered hallucinatory images, such as the visceral "Horror Strip" (page 95) and the abstract "Cotton Picasso" (page 92), positions Beane alongside visionaries like Yayoi Kusama and Frida Kahlo in transforming psychological turmoil into transcendent art. Galleries from

All 5 Releases


More Releases for Therapeutic

Exosome Therapeutic Market : Detailed Overview
Introduction: The exosome therapeutic market is a rapidly emerging segment in the field of regenerative medicine and drug delivery. Exosomes are extracellular vesicles naturally released by cells that play a crucial role in cell communication and genetic material transfer. They have gained attention for their potential applications in treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. As a novel therapeutic platform, exosomes provide significant advantages such as low immunogenicity,
Parkinson's Disease Therapeutic Market Hope for Patients: The Parkinson's Diseas …
Parkinson's Disease Therapeutic Market worth $6.51 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)),
Global Remote Therapeutic Monitoring Market
According to a new market research report published by Global Market Estimates, the Global Remote Therapeutic Monitoring Market is projected to grow at a CAGR of 17.4% from 2023 to 2028. Medsien, Intellihinc, Zimmer Biomet, Owlytics Healthcare, Limber Health, Medistics, RxCap, Propeller Health, HealthArc, CENSON Health, and B Castle Smith & Co., are some of the key players in the remote therapeutic monitoring market. Browse 147 Market Data Tables and 115
Europe Digital Therapeutic (DTx) Market
Europe Digital Therapeutic (DTx) Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Europe Digital Therapeutic (DTx) Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Europe Digital Therapeutic (DTx) market examines the primary segments of the market. This intelligent study provides historical data from forecast.It also provides the details such as whether the customers
Recombinant Therapeutic Antibodies and Proteins Market continues to expand with …
Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies
Therapeutic Vaccine Market 2020 - 2028 Top Companies Agenus Inc., Argos Therapeu …
This detailed market study covers therapeutic vaccine market growth potentials which can assist the stake holders to understand key trends and prospects in therapeutic vaccine market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The